Relay Therapeutics Inc (NASDAQ: RLAY) kicked off on Tuesday, down -3.57% from the previous trading day, before settling in for the closing price of $6.16. Over the past 52 weeks, RLAY has traded in a range of $5.60-$12.14.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 319.82% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 8.22%. With a float of $124.33 million, this company’s outstanding shares have now reached $127.46 million.
In an organization with 323 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 58.64%, operating margin of -3926.55%, and the pretax margin is -3449.92%.
Relay Therapeutics Inc (RLAY) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Relay Therapeutics Inc is 25.72%, while institutional ownership is 55.84%. The most recent insider transaction that took place on Oct 28 ’24, was worth 9,823. In this transaction an insider of this company sold 1,621 shares at a rate of $6.06, taking the stock ownership to the 390,063 shares. Before that another transaction happened on Oct 28 ’24, when Company’s Chief Financial Officer sold 6,802 for $6.06, making the entire transaction worth $41,220. This insider now owns 306,391 shares in total.
Relay Therapeutics Inc (RLAY) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -0.67 earnings per share (EPS), higher than consensus estimate (set at -0.73) by 0.06. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.59 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 8.22% per share during the next fiscal year.
Relay Therapeutics Inc (NASDAQ: RLAY) Trading Performance Indicators
Take a look at Relay Therapeutics Inc’s (RLAY) current performance indicators. Last quarter, stock had a quick ratio of 18.42. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 99.33.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.61, a number that is poised to hit -0.61 in the next quarter and is forecasted to reach -2.64 in one year’s time.
Technical Analysis of Relay Therapeutics Inc (RLAY)
Let’s dig in a bit further. During the last 5-days, its volume was 1.49 million. That was better than the volume of 1.45 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 55.56%. Additionally, its Average True Range was 0.39.
During the past 100 days, Relay Therapeutics Inc’s (RLAY) raw stochastic average was set at 6.64%, which indicates a significant decrease from 37.78% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 38.62% in the past 14 days, which was lower than the 93.43% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.76, while its 200-day Moving Average is $7.47. However, in the short run, Relay Therapeutics Inc’s stock first resistance to watch stands at $6.11. Second resistance stands at $6.28. The third major resistance level sits at $6.39. If the price goes on to break the first support level at $5.84, it is likely to go to the next support level at $5.73. Assuming the price breaks the second support level, the third support level stands at $5.56.
Relay Therapeutics Inc (NASDAQ: RLAY) Key Stats
The company with the Market Capitalisation of 994.26 million has total of 133,890K Shares Outstanding. Its annual sales at the moment are 25,550 K in contrast with the sum of -341,970 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -92,210 K.
